FDA pushes back Capricor's Deramiocel PDUFA date to November 22, 2026Aug 24Regulatory milestoneCapricor Therapeutics, Inc.
Capricor gives update on Deramiocel BLA after adcomm setback, reports Q2 2026 resultsAug 13Quarterly updateCapricor Therapeutics, Inc.
FDA advisory panel votes against Deramiocel for DMD cardiomyopathy, 9 to 3Jul 30Regulatory milestoneCapricor Therapeutics, Inc.
Lancet publishes Capricor's HOPE-3 data as FDA review continuesJul 29Clinical readoutCapricor Therapeutics, Inc.
Capricor discloses San Diego HQ lease tied to Deramiocel FDA decisionJul 14PartnershipCapricor Therapeutics, Inc.
Sign in